Your browser doesn't support javascript.
loading
Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation.
Ortmann, Christina A; Dorsheimer, Lena; Abou-El-Ardat, Khalil; Hoffrichter, Jennifer; Assmus, Birgit; Bonig, Halvard; Scholz, Anica; Pfeifer, Heike; Martin, Hans; Schmid, Tobias; Brüne, Bernhard; Scheich, Sebastian; Steffen, Björn; Riemann, Julia; Hermann, Stella; Dukat, Alexandra; Bug, Gesine; Brandts, Christian H; Wagner, Sebastian; Serve, Hubert; Rieger, Michael A.
Affiliation
  • Ortmann CA; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Dorsheimer L; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Abou-El-Ardat K; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Hoffrichter J; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Assmus B; Department of Medicine, Cardiology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Bonig H; Institute for Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood Service BaWüHe, Frankfurt am Main 60528, Germany.
  • Scholz A; Institute for Biochemistry I, Faculty of Medicine, Goethe University, Frankfurt am Main 60528, Germany.
  • Pfeifer H; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Martin H; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Schmid T; Institute for Biochemistry I, Faculty of Medicine, Goethe University, Frankfurt am Main 60528, Germany.
  • Brüne B; Institute for Biochemistry I, Faculty of Medicine, Goethe University, Frankfurt am Main 60528, Germany.
  • Scheich S; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Steffen B; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Riemann J; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Hermann S; Ambulantes Krebszentrum Schaubstrasse (AKS), Frankfurt am Main 60596, Germany.
  • Dukat A; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany; Ambulantes Krebszentrum Schaubstrasse (AKS), Frankfurt am Main 60596, Germany.
  • Bug G; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany.
  • Brandts CH; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany; University Cancer Center Frankfurt (UCT), Goethe University Hospital, Frankfurt am Main 6
  • Wagner S; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Serve H; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Rieger MA; Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt am Main 60590, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. Electronic address: m.rieger@em.uni-frankfurt.de.
Cell Rep ; 27(7): 2022-2028.e3, 2019 05 14.
Article in En | MEDLINE | ID: mdl-31091442
ABSTRACT
Clonal hematopoiesis of indeterminate potential (CHIP) is caused by recurrent somatic mutations leading to clonal blood cell expansion. However, direct evidence of the fitness of CHIP-mutated human hematopoietic stem cells (HSCs) in blood reconstitution is lacking. Because myeloablative treatment and transplantation enforce stress on HSCs, we followed 81 patients with solid tumors or lymphoid diseases undergoing autologous stem cell transplantation (ASCT) for the development of CHIP. We found a high incidence of CHIP (22%) after ASCT with a high mean variant allele frequency (VAF) of 10.7%. Most mutations were already present in the graft, albeit at lower VAFs, demonstrating a selective reconstitution advantage of mutated HSCs after ASCT. However, patients with CHIP mutations in DNA-damage response genes showed delayed neutrophil reconstitution. Thus, CHIP-mutated stem and progenitor cells largely gain on clone size upon ASCT-related blood reconstitution, leading to an increased future risk of CHIP-associated complications.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cells / Hematopoietic Stem Cell Transplantation / Hematopoiesis / Mutation / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Hematopoietic Stem Cells / Hematopoietic Stem Cell Transplantation / Hematopoiesis / Mutation / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article